Introduction
Drug Regulatory Affairs has evolving and growing and is the one which is least impacted during the Acquisition and Merger, and also during recession. Global harmonization in standards has led to consistent approach in regulatory submissions. The Systematic formulation development acts as a back bone for any dossier preparation in export registration. (1) The Registration requirement are different for different countries so it is difficult for any company to develop product for each region Therefore; we need to consider majority of requirements during technical data submission which will help in export registration therefore, harmonisation occurs as clusters in Emerging markets are necessary for submission of dossier eg. specific medical need of patients in these regions. One way to launch new drugs in a timely manner in emerging markets is to include majority of patients from relevant countries in clinical development programs. This practice is routine for most pharmaceutical companies. These development programs attributed to longer life expectancy and lifestyle changes that are possible through rapid economic growth. (2) Emerging markets are important and expanding globally and has raised the demand for general and lifesaving medicines. Regional cooperation is required to ensure that the scientific capacity is developed. Apart from this, regional manufacturing capacity is the most expected way to enable economic growth, specified quality standards should meets international export requirements. Legislative and political factors are the most critical one, countries need to have support to develop effective national legislation, as well as cooperating regionally which helps to access to essential medicines. (2) Pharmaceutical Companies and regulatory agencies are collaborating for improving drug development process and approval ex: ICH guidelines for eCTD submission and QbD which contribute to better first time product quality shortening the review time required by regulatory agency and these guidelines are well accepted by regulated markets and some countries of semi regulated market like India and China uses the CTD format. (2) Pharmaceutical Market is divided into following groups (3): 10
Emerging Market overview
Emerging market consists of mainly the countries from Asia pacific, Latin America, Africa and Gulf countries. These countries are differing in their region and also in many other aspects as regulation of Pharmaceuticals, Using different Guidelines for registration, registration fees, Requirements to maintain registration, duration of registration Patent regulation and legislation for the drug. (1) The Asia Pacific market is expected to grow from USD 187 billion in 2009 to nearly USD 275 billion in 2013 and has developed to a great extend till date, at a CAGR of more than 13%. The main reason behind this is, due to low cost availability of generic medicines, rising income, growth of business and health insurance schemes. (1) The optimization in requirements is mandatory and can be judged by the incidence of higher cost involved in availability of drugs, research and development facilities. For better treatment safety and efficacy for the drugs must be justified and rationalize for public security. The quality, safety and efficacy data has its own importance in the registration dossier. The commercial significance of markets is increasing globally. (1) WHO is continued to play a major role in terms of scientific capacity development, through its prequalification project and other activities. Given that the quality of pharmaceuticals is such a major issue, the WHO and other international organizations, such as developed country drug regulatory authorities, should be encouraged and supported to expand their current programmes which are supporting to developing countries. Ministry of Health of GCC states (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia and UAE) are regulatory authorities for the regional pharma sector. They also regulate prices of pharmaceutical products and bring about harmonization of varying prices and the regulatory process, the GCC implemented a centralized system, Gulf Central Committee for Drug Registration (GCC-DR) in May 1999, which currently runs parallel to the regulatory regimes in the region. The Latin American markets are forecast to grow at a robust 10% CAGR from USD 37.6 billion in 2009 to USD 62 e-ISSN: 2321-6794
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billion in 2012, due to changes in regulatory policies and increased manufacturing base for generic drugs by the US drug makers. Strong economic growth in these countries will drive lucrative growth in these markets.
The regulatory regime in LATAM countries can be divided into three categories i.e. Countries which have established regulations (Brazil, Mexico, and Venezuela) to demonstrate the efficacy, safety through clinical trials or Bioequivalence studies with the innovator's product in the drug approval process. The countries as Argentina, Chile, Columbia, Ecuador, and Paraguay also have the regulations for registration of new or generic drug but are less stringent from first category. The last category of countries (Guatemala, Barbados, Bolivia, Nicaragua and Peru) has imperfectly formed drug regulations for the approval of drugs. Rest of the region countries insist on following ICH region for some data like stability, clinical trials though it follows majorly its own regulations e.g., the ASEAN countries require data as per ASEAN CTD which is same as ICH CTD for data requirements organized in Parts. The brief contents of CTD and major requirements for various regions are tabulated in Table 2 . (1) There is a difference in format for documents between ICH CTD and ACTD. As there are 5 modules in ICH CTD named as Module-I to Module-V and the documents in ACTD are named as part-I to part-IV because it does not involve common technical document overview and summaries like in CTD. The rest of the documents are administrative document and product information, quality document, nonclinical documents and clinical documents. (5) There are some additional documents required at the time of the approval of drug in various countries as samples of drug are not required in Singapore, Malaysia and Indonesia and required in Thailand and Philippines. Another document is the Certificate of Pharmaceutical Product (COPP) and manufacturing license which is required in all countries under the ASEAN region. GMP (Good Manufacturing Practices) is another document, which is PICs in Singapore, Malaysia and Indonesia but not in Thailand and Philippines. (6)
Research and Development focus
With the growing emphasis on the timely introduction of life saving drugs for diseases in Asia, there has also been an increase in discovery research for diseases that are more prevalent in the region than in the United States and in Europe. (2) Emerging Markets: Key Challenges ( 
Regulatory Barriers
There are key regulatory barriers affecting the drug lag witnessed in the emerging countries. These barriers are Western approval, CPP, GMP, pricing approval, document authentication and harmonization. These barriers need to be overcome in order to reduce drug lag further in the future. (2) Strategy for Success (2)  Proper time management as the registration and company success depends upon the time taken by product to reach the market first Know and be compliant with national requirements.  Health authority relationships critical, local talent important.  Training programme and incentives for agency staff.
 Frequent and early communication with Health
Authorities.  Early integration of emerging market strategy into development plans and integration of regional requirements into a global regulatory plan.  Rapid responses and rapid publishing support 24/7.  Be the first with a product for an unmet medical indication and proper invest in the region.  Particle size distribution, Hygroscopicity, granularity, flowability etc. should be described in detail.
Registration Requirements for Emerging Markets

Manufacturing Process & Process Controls
 Detail information of manufacturing formula.  Detail steps of API synthesis and purification are mentioned.  The specifications of reagents, starting materials, intermediates, catalysts, and solvents used in the reaction.  Type of equipment, its capacity and scale.  In process test and control detail  Master formula and batch manufacturing record are mentioned.  Process validation protocol (report of 3 batches of same size and similar batch) are submitted.
Control of Critical Steps & Intermediates:
 The Control of Materials should be complemented by the supplier & the In-house Certificate of analysis.  Flow chart of critical steps and in process control is mentioned.  Environmental condition such as temperature, humidity and air flow range should be mentioned.
Process Validation and/or Evaluation
 During process validation three consecutive batches must be provided. Three different batches are performed for stability study is performed on Process Validation. ). An XRD test report should be included.  The spectral data such as NMR, X-ray Diffraction, Elemental Analysis and IR as a means for evidence of chemical structure are describe in detail.
Formulation Development
 The final product is manufactured using critical raw materials from two different suppliers. However, no special attention has been given to differences in quality of the end product.  The development report should be prepared by taking into consideration QbD concept.  The process control details such as moisture (range), blend uniformity, bulk and tapped densities and particle size distribution should be provided.  Dissolution methods will have to be developed, the influence of particle size will have to be studied.
Overages
 Formula of API assay potency calculation details provided.
Impurities (8, 9) The following factors to be considered while fixing the specification limits of impurities are;
 API impurity limits data (COA)  Check ICH requirements.
 Check pharmacopoeia limits, if any.  API stability data.  Finished product stability data etc.  Apart from the normal Process impurities, Residual Solvents & Degradation impurities, impurities due to the Starting material should be as per Pharmacopoeias limit.  The impurities must be also appropriately captured in the Specification of the Final Product.  The product from each source impurity profiling should be provided.  Potential impurities should be described in the impurity profile.  For the impurities measurement methods should be mentioned.  In the synthesis hazardous reagents and inorganic toxic substances are used in the reaction their residual limits should be given.  The unknown impurities present in the API should be not more than ICH limits.
Analytical Procedures (10)  The method reference should be included in the specification page of the DMF.  The Limit of Quantification (LOQ) and the limit of detection (LOD) should be provided for GC and HPLC methods used to control residual solvents and impurities in the Drug substance.  Definite validated GLC/HPLC methods for qualify the impurities should be available. TLC report should be provided.  In MOH laboratory the tests performed for validation are indicated vague.  The method validated should be the same as that of the final method adopted to test the Drug substance are mentioned.  Typical chromatograms must be provided for a particular batch of the API.  In many countries report of validation of analytical method are not mandatory.  Verification of non-compendia method needs to be validated by agency if required.  The assay limits at release should have been revised to 95-105% wider limits for shelf life could be applied.
Batch Analysis
 Report of 3 initial batches of API production should be provided  Batch should be selected on the bases of the regulatory requirement of the countries (ICH demand COA report Finished product Specification (12)  It should be prepared as WHO and ICH Q6 method of analysis. (13)  Ability of pharmaceutical product to retain its property within specified limits throughout shelflife. 
Stability Data and Stability Protocol
Control of Materials
 The residual metals from the reaction procedure are poorly addressed.  The raw materials, reagents, intermediates and solvents used in the process are not described properly for possible impurities.  In FP (Finished Product) specification microbial limit is not included. 
Control of Critical Steps & Intermediates
Process Validation and Evaluation
 Three different batches are performed for stability study not performed on Process Validation.
Elucidation of Structure and other Characteristics
 The spectral data such as NMR, X-ray Diffraction, Elemental Analysis and IR as a means for evidence of chemical structure is missing.  For Drug substance spectral graphs for UV Spectra, NMR & IR studies performed are unacceptable and interpretation of the studies is inadequate.
Impurities
 Toluene is used as solvent in the synthesis but not tested the same for presence of residual it and benzene class I solvent used in the synthesis of the drug substance and products. The residual limits for class I solvent are not described tested at any point.  Potential impurities are not described in the impurity profile  In the synthesis raw materials and intermediates are used. Their specifications of are not described.
Although hazardous reagents and inorganic toxic substances are used in the reaction but the same residual limits are not given.  In the reaction process Excipients used which may carry reactive impurities such as Hydrogen peroxide (other oxidized species), formaldehyde and Formic Acid. Justification for the use of this Excipient is not provided as per Impurities in residual solvents (ICH Q3C).  Absence of Genotoxicity study, testing and data designed to detect compounds that cause genetic damage.
Control of Drug Substance
 The quality of the APIs meet only the requirements of specific monographs but does not meet to specifications described in the general monographs of a pharmacopoeia.  Catalyst if any used in the synthesis of the API may be controlled (not necessary if absence in 3 batches shown)
Analytical Procedures
 Assay & Related substances will have to have a Stability indicating method (although the compendia method may be titration/TLC etc.)  The Limit of Quantification (LOQ) and the limit of detection (LOD) are not provided for GC and HPLC methods used to control residual solvents and impurities in the Drug substance.  The method used for the study of Drug substance is not specific. For the Analysis of impurities specific method is used which are not provided.  Carcinogenic solvents like Methanol Acetone and IPA have been used in synthesis. However, these solvents are not analyzed for chance contamination of Class I solvents from which they are prepared.  A check on the presence of Genotoxic impurities needs to be studied which may present in the Drug product.  Certificate of Analysis (COA) and other Quality Control (QC) documents are not signed dated and certified by Quality Assurance (QA) department.
Batch Analyses
 Significant differences between the API manufacturers and FPP manufacturer's batch study/analysis were noted for acetone, isopropyl alcohol and methanol  The batch formula not mentioned for the exhibit as well as the proposed commercial batch eg. In drug formulation titanium dioxide is used as Opacifier but mentioned in batch formula. Also the complete composition of the coating materials is not provided.  The information on some hazardous materials like reagent and solvent is hidden.
Stability Data
 Do not consider zone-conditions for Real-time stability studies.  In stability report the packaging details are missing.  The actual studies for stability are not provided.
Data is provided from literature of forced degradation study.  Microbial Attributes test not provided and/or not provided at Initial and final stage in stability data.
Container Closure System
 Primary packaging material Certificate of Analysis (COA) & Standard Test Procedure (STP) are not given.  Pack style and pack size discussion is not provided.  For final packaging the extractable and leachable study for the plastic containers and stoppers used for the drug product packaging is not provided.
Microbiological Attributes
 Microbial Contamination results are missing. Pathogen Count and Total Count not provided.
Harmonization
 According to WHO, the main cause behind the harmonization is to improve the availability of pharmaceutical and respond to international trade pressure by providing sufficient comprehensive and standardization technical rules on safety quality and efficiency of drug. (17, 18) 
Initiation of harmonization in ASEAN
 It was evaluated that due to lack of harmonization in emerging markets countries which lead to unnecessary duplication of work and waste of valuable resources and eventually increase drug lag. The first harmonization was initiated by the Association of South East Asian Nations (ASEAN) in 1967. The harmonization was occurs in clusters e.g. ASEAN and Gulf Countries but this should be reformed after translation. Format for marketing application resembles with the EU submission format. Few countries as India, Ukraine, Russia, South Africa and some newly harmonized countries uses the format almost same as EU-CTD format. Thus they are harmonized in regards of formats.
Harmonization with GMP has help to improve pharmaceutical trade between ASEAN member countries by removing impeding barriers. with the harmonized regulations in their respective regions.
(3)
Effect of ASEAN harmonization of guidelines on pharmaceutical market
Harmonization of regulatory guidelines by ASEAN countries has a huge impact on drug approval as well as pharmaceutical market. Harmonization procedure for drug approval and registration has a positive effect on pharmaceutical market in this group of countries. The total trade of countries has been increase by implementing CTD format for registration of drug and has strong position in global level. (19) (17)  The Harmonization of Drug Endorsement in Africa (HHMA) initiative, led by the African Union (AU), made it possible to formulate proposals for the harmonization of pharmaceutical regulations within the different economic community's sub-regional level.  In western African countries the process of harmonization has been carried out by western African economic monetary union (WAEMU) which constitutes the legal basis for the process of harmonization of pharmaceutical regulations in this union.  In Central Africa, the process of harmonization is essentially carried out by the Economic Community of Central African States (CEMAC), which after a situational analysis in prompted the adoption  It must therefore be concluded that, in both regions, the process of harmonizing pharmaceutical regulations is dynamic and not yet completed. The different African sub-regions need to draw inspiration from each other's specific experiences to optimize the process of harmonizing pharmaceutical regulations in Africa. (20, 21)  The seven Gulf Cooperation Council (GCC) States (Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates and Yemen) also took the initiative after the EU centralized procedure to improve patients' access to safe and effective medicines in the GCC Region by The GCC Central Drug Registration (GCC-DR) Committee is composed of two members from each of the seven countries.  The procedure is carried out by selecting two authorities alphabetically to review a registration dossier. However, all the GCC authorities are equally responsible for evaluating the quality, safety and efficacy of medicines and therefore all the seven states are provided with copies of the product registration dossier for their individual assessments.  The pharmaceutical market in GCC countries exceeds 6 billion USD. This market is growing rapidly and is expected to reach around 10 billion USD by 2020. The aforesaid meeting, the first ever of its kind in that sector, is aimed at achieving several objectives including to create a forum for the exchange of ideas and dialogue among pharmaceutical companies in GCC, propose a multiclient study that will address the needs of the pharmaceutical industry in the region, and identify the need for establishing a pharmaceutical trade association for GCC producers.  Due to the advancement in Information technology, regulatory authorities from regulated countries throughout the globe started to accept data in electronic format either in eCTD (Electronic common technical document)/ NeeS (Non eCTD electronic submission).  The international protection of IPR assumes far greater importance today because of the huge amount of cross-border business. As such, the role of organizations, such as the World Intellectual Property Organization, becomes very important in order to seek harmony amongst national laws. The international treaties have formulated rules in relation to areas such as international filing, disclosure, and compulsory licensing. These treaties and conventions contribute to the process of harmonization of patent laws.  The urgent requirement to rationalize & harmonize regulation was impelled by instance of rising cost of Health care, R & D & need to meet the public requirement to approach for the safe & efficacious treatments to patient in need. ICH committee has given priority to harmonize the format of reporting data for qualities.  Advancement in terms of quality of Pharmaceutical products can be achieved through Quality management system that confirms to international quality standards like FDA, MHRA, WHO GMP & in terms of technology can be achieved improving local R & D capabilities & ICH Q 11-QbD (Quality by design).  Hence, experts from all regions should go with harmonization of regulatory requirements throughout the globe & produce a single harmonized marketing application for registration of drug product/API that will used by all health authorities worldwide.
Initiation of harmonization in African countries
Initiation of harmonization in GCC countries
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Summary and Discussion
Meals taken are as per specification (composition) and time administration depends on type of study.
Major holdup
Obtaining Certificate of Pharmaceutical product (CPP) may delay the process, Administrative procedures in individual countries, time delay in Approval. 
Conclusion
A comparison against the registration requirements for different group of emerging countries has been done to judge the difference in regulatory requirements of different countries. Since the world is divided in the drug approval procedures, it is important for the manufacturers, especially the generic companies, to carefully assess the market interest, cost of development, target regions, regulatory requirements before the development of drugs.
By having a view at the different regulatory environment, it is impossible to get global market harmonization and approval at same time and launch in all the regions at once. Hence, it is necessary to understand and define the clear regulatory strategy by looking at the target regions, different patent terms and its extension, various application possibilities, data requirements, deadlines for launching products to be marketed in different regions. This eliminates unnecessary studies, minimizes the delay in drug approvals and subsequent launch, and reduces overall cost of research and development.
Export market demands good quality dossier which can be generated through systematic Formulation Development and having the knowledge of guidelines of respective country. The proper planning and execution of Formulation development will help in quality dossier & in answering queries from Regulatory authorities.
Since the world is divided in regulated and semi regulated markets the drug approval procedures with the technical data became difficult to register in those countries thus, it is important especially for the generic manufacturers, to carefully judge the market need different patent terms and its extension, various application possibilities, data requirements, potential timeline for marketing launch in different regions Development Cost, target regions, & regulatory requirements before the development of drugs. Hence it is critical to plan and co-ordinate all the activities for successful launch of product in the market on time.
Although the requirements are harmonized in regulated countries by CTD (Common technical document) filing, yet others have enormous diversity in requirements. ICH brought regulatory authorities and pharmaceutical industries of Europe, Japan and US together for various aspects of drug registration should bring some requirement to be harmonized there in emerging market, so that the drug approval process becomes easy and duplication of work and waste of valuable resources avoided. By examining these markets individually, it would be easier to target the areas where they can specifically improve their regulatory barriers, thus leading the way for the emerging markets.
Finally, there needs to be a reassertion that the purpose of drug registration is to protect the public health, not to facilitate profit of pharmaceutical manufacturers. Registration should be seen as a critical step in ensuring access to safe and effective medicinal product.
